RealFeedApp Kymera Therapeutics to announce KT-621 trial data before year-end
Kymera Therapeutics plans to release data from a mid-stage clinical trial of KT-621 for eczema before year-end. Jefferies analysts describe the upcoming results as one of the most impactful immunology and inflammatory disorder readouts this year.
- Field
- drugs and trials
- What they did
- Biotech company Kymera Therapeutics plans to announce data from a mid-stage clinical trial of its lead asset, KT-621, for treating eczema before the end of the year.
- Why it matters
- The upcoming results could have major consequences for Kymera, its growing list of competitors, and the millions of people who live with eczema in the United States.
#clinical trial#eczema#kymera therapeutics#kt-621#dupixent#sanofi
